ABSTRACT
Among cardiovascular disease (CVD) biomarkers, the mitochondrial DNA copy number (mtDNAcn) is a promising candidate. A growing attention has been also dedicated to trimethylamine-N-oxide (TMAO), an oxidative derivative of the gut metabolite trimethylamine (TMA). With the aim to identify biomarkers predictive of CVD, we investigated TMA, TMAO and mtDNAcn in a population of 389 coronary artery disease (CAD) patients and 151 healthy controls, in association with established risk factors for CVD (gender, age, hypertension, smoking, diabetes, glomerular filtration rate (GFR)). MtDNAcn was significantly lower in CAD patients and in hypertensive subjects; it correlates with GFR and TMA, but not with TMAO. A biomarker including mtDNAcn, gender, and hypertension (but neither TMA nor TMAO) emerged as a good predictor of CAD. Our findings support the usage of mtDNAcn as a plastic biomarker to monitor the exposure to risk factors and the efficacy of preventive interventions for a personalized CAD risk reduction.
Highlights
- mtDNAcn measured in whole blood is associated to the cardiovascular health status in humans;
- mtDNAcn is reduced in CAD and hypertension, and inversely correlates with GFR;
- mtDNA, gender and hypertension together represent a good predictive biomarker for CAD;
- TMA metabolism is different in healthy and CAD subjects;
- TMA and TMAO are not good predictors of CAD.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03899389
Funding Statement
Funding for reagents were provided by Prof. Rosita Gabbianelli (FPA000033), and Ministry of Science and Higher Education, Poland, grant no. DIR/WK/2017/01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Bioethical Committee (RBC) in Gdansk (KB-27/16 and KB 32-17) and registered at clinicaltrials.gov (NCT03899389).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
ABBREVIATION LIST
- mtDNA
- Mitochondrial DNA
- mtDNAcn
- Mitochondrial DNA copy number
- CVD
- Cardiovascular disease
- CAD
- Coronary artery disease
- ATP
- Adenosine triphosphate
- BMI
- Body Mass Index
- TMA
- Trimethylamine
- TMAO
- Trimethylamine-N-oxide
- NUMT
- Nuclear mitochondrial DNA sequence
- nDNA
- nuclear DNA
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos